Your browser doesn't support javascript.
loading
Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum.
Shareef, M S; Munro, L R; Owen, R G; Highet, A S.
Affiliation
  • Shareef MS; Department of Dermatology, York Teaching Hospital, York, UK. m.shareef@nhs.net
Clin Exp Dermatol ; 37(2): 146-8, 2012 Mar.
Article in En | MEDLINE | ID: mdl-22103549
ABSTRACT
Pyoderma gangrenosum (PG) may be associated with inflammatory disorders and haematological conditions such as monoclonal gammopathy of uncertain significance (MGUS). We report the case of a 53-year old man who had PG and MGUS. After treatment with infliximab for the PG, he developed myeloma. The course of events in this case suggests that infliximab facilitated the progression from MGUS to myeloma.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunoglobulin A / Tumor Necrosis Factor-alpha / Pyoderma Gangrenosum / Hypergammaglobulinemia / Anti-Inflammatory Agents / Antibodies, Monoclonal / Multiple Myeloma Limits: Humans / Male / Middle aged Language: En Journal: Clin Exp Dermatol Year: 2012 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunoglobulin A / Tumor Necrosis Factor-alpha / Pyoderma Gangrenosum / Hypergammaglobulinemia / Anti-Inflammatory Agents / Antibodies, Monoclonal / Multiple Myeloma Limits: Humans / Male / Middle aged Language: En Journal: Clin Exp Dermatol Year: 2012 Document type: Article